Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Monday's Bonus Article Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best times in history to build wealth—especially if you think long term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, adding that recent selling has more to do with valuation concerns and interest-rate doubts than any fundamental breakdown. Why the Market Pulled Back Green attributes the dip to two main factors. First, investors are starting to question elevated tech and AI valuations, particularly as earnings season brings those expectations into focus. Second, inflation readings and softer hiring data have dampened hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" posture, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict where the market will be next week, Green urges investors to zoom out. He calls himself "a long-term optimist," and notes that, historically, the market's trend has been up and to the right. For traders, a degree of short-term caution may be warranted. But for long-term investors, these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in uncertain times is insider buying. Green recommends paying attention when officers and directors—people with access to non-public financial information—are investing in their own companies. Track insider trading activity to see which stocks corporate executives are buying, not just selling. While insiders aren't always right, their actions can be a useful signal when markets are volatile. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and calls it "a good feeling" to know you're clear of so many deadly diseases—especially cancers like pancreatic that often go undetected until late stages. With FDA fast-track status and potential insurance reimbursement on the horizon, Green sees GRAIL's roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech investing carries risk: most drugs never make it through all three phases of clinical trials. Still, large pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) are actively acquiring promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as an example: the company invested in a private prostate cancer drug before that drug received FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. He also argues biotech is particularly attractive now because healthcare is largely recession‑resistant. People need treatment regardless of the economic cycle. For investors looking to weather volatility, sectors such as healthcare, utilities, consumer staples, and food companies typically offer steady demand and less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green contends the American Dream is far from dead. He wrote The American Dream to counter the narrative that it's out of reach after seeing polls indicating nearly 70% of Americans believe it's no longer attainable. The reality, he says, is that with access to low-cost investment tools, no‑commission trading, and abundant information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to do it. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save consistently and leave the money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says there are still ways in. Mortgage rates have doubled and prices are up about 50% since the pandemic, but creative options exist. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method known as a "contract for deed." It might not get you the perfect house immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green's message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
